Targeting Ionotropic Glutamate Receptors in the Treatment of Epilepsy

Overview

Journal Curr Neuropharmacol

Publisher Bentham Science Publishers

Date 2020 Sep 2

PMID 32867642

Citations 14

Authors

Roberta Celli

Francesco Fornai

Affiliations

Soon will be listed here.

Abstract

Background: A dysfunction in glutamate neurotransmission is critical for seizure. Glutamate is the major excitatory drive in the cerebral cortex, where seizures occur. Glutamate acts via (i) ionotropic (iGlu) receptors, which are ligand-gated ion channels mediating fast excitatory synaptic transmission; and (ii) G proteins coupled metabotropic (mGlu) receptors.

Objective: To overview the evidence on the role of iGlu receptors in the onset, duration, and severity of convulsive and non-convulsive seizures to lay the groundwork for novel strategies for drug-resistant epilepsy.

Methods: We used PubMed crossed-search for "glutamate receptor and epilepsy" (sorting 3,170 reports), searched for "ionotropic glutamate receptors", "AMPA receptors", "NMDA receptors", "kainate receptors", "convulsive seizures", "absence epilepsy", and selected those papers focusing this Review's scope.

Results: iGlu receptor antagonists inhibit, whereas agonists worsen experimental seizures in various animal species. Clinical development of iGlu receptor antagonists has been limited by the occurrence of adverse effects caused by inhibition of fast excitatory synaptic transmission. To date, only one drug (perampanel) selectively targeting iGlu receptors is marketed for the treatment of focal epilepsy. However, other drugs, such as topiramate and felbamate, inhibit iGlu receptors in addition to other mechanisms.

Conclusion: This review is expected to help dissect those steps induced by iGlu receptors activation, which may be altered to provide antiepileptic efficacy without altering key physiological brain functions, thus improving the safety and tolerability of iGlu-receptor directed antiepileptic agents. This effort mostly applies to drug resistant seizures, which impact the quality of life and often lead to status epilepticus, which is a medical urgency.

Citing Articles

AMPA Receptors in Synaptic Plasticity, Memory Function, and Brain Diseases.

de Leon-Lopez C, Carretero-Rey M, Khan Z Cell Mol Neurobiol. 2025; 45(1):14.

PMID: 39841263 PMC: 11754374. DOI: 10.1007/s10571-024-01529-7.

Increased GluK1 Subunit Receptors in Corticostriatal Projection from the Anterior Cingulate Cortex Contributed to Seizure-Like Activities.

Li X, Shi W, Zhao Z, Matsuura T, Lu J, Che J Adv Sci (Weinh). 2024; 11(39):e2308444.

PMID: 39225597 PMC: 11497107. DOI: 10.1002/advs.202308444.

Presynaptic antiseizure medications - basic mechanisms and clues for their rational combinations.

Czapinska-Ciepiela E, Luszczki J, Czapinski P, Czuczwar S, Lason W Pharmacol Rep. 2024; 76(4):623-643.

PMID: 38776036 PMC: 11294404. DOI: 10.1007/s43440-024-00603-7.

Origanum majorana L. polyphenols: antiepileptic effect, in silico evaluation of their bioavailability, and interaction with the NMDA receptor.

Amaghnouje A, Chebaibi M, Aldossari S, Ghneim H, Amrati F, Es-Safi I Front Chem. 2024; 11:1257769.

PMID: 38313221 PMC: 10835798. DOI: 10.3389/fchem.2023.1257769.

Integrated Macrogenomics and Metabolomics Explore Alterations and Correlation between Gut Microbiota and Serum Metabolites in Adult Epileptic Patients: A Pilot Study.

Zhou K, Jia L, Mao Z, Si P, Sun C, Qu Z Microorganisms. 2023; 11(11).

PMID: 38004640 PMC: 10672912. DOI: 10.3390/microorganisms11112628.

References

Smolders I, Bortolotto Z, Clarke V, Warre R, Khan G, ONeill M . Antagonists of GLU(K5)-containing kainate receptors prevent pilocarpine-induced limbic seizures. Nat Neurosci. 2002; 5(8):796-804. DOI: 10.1038/nn880. View

Chang F, Fan P, Weng W, Chang C, Lee W . The efficacy of perampanel in young children with drug-resistant epilepsy. Seizure. 2020; 75:82-86. DOI: 10.1016/j.seizure.2019.12.024. View

Ngomba R, van Luijtelaar G . Metabotropic glutamate receptors as drug targets for the treatment of absence epilepsy. Curr Opin Pharmacol. 2018; 38:43-50. DOI: 10.1016/j.coph.2018.01.012. View

Ramakers G, Peeters B, Vossen J, Coenen A . CNQX, a new non-NMDA receptor antagonist, reduces spike wave discharges in the WAG/Rij rat model of absence epilepsy. Epilepsy Res. 1991; 9(2):127-31. DOI: 10.1016/0920-1211(91)90023-9. View

Spritzer S, Bravo T, Drazkowski J . Topiramate for Treatment in Patients With Migraine and Epilepsy. Headache. 2016; 56(6):1081-5. DOI: 10.1111/head.12826. View

Tovar K, Westbrook G . Modulating synaptic NMDA receptors. Neuropharmacology. 2016; 112(Pt A):29-33. PMC: 5075510. DOI: 10.1016/j.neuropharm.2016.08.023. View

Gilron I, Max M, Lee G, Booher S, Sang C, Chappell A . Effects of the 2-amino-3-hydroxy-5-methyl-4-isoxazole-proprionic acid/kainate antagonist LY293558 on spontaneous and evoked postoperative pain. Clin Pharmacol Ther. 2000; 68(3):320-7. DOI: 10.1067/mcp.2000.108677. View

Jette N, Marson A, Hutton J . Topiramate add-on for drug-resistant partial epilepsy. Cochrane Database Syst Rev. 2002; (3):CD001417. DOI: 10.1002/14651858.CD001417. View

Cokic B, Stein V . Stargazin modulates AMPA receptor antagonism. Neuropharmacology. 2008; 54(7):1062-70. DOI: 10.1016/j.neuropharm.2008.02.012. View

10.

Shank R, GARDOCKI J, Streeter A, Maryanoff B . An overview of the preclinical aspects of topiramate: pharmacology, pharmacokinetics, and mechanism of action. Epilepsia. 2000; 41(S1):3-9. View

11.

Nowak L, Bregestovski P, Ascher P, Herbet A, Prochiantz A . Magnesium gates glutamate-activated channels in mouse central neurones. Nature. 1984; 307(5950):462-5. DOI: 10.1038/307462a0. View

12.

Russo E, Gitto R, Citraro R, Chimirri A, De Sarro G . New AMPA antagonists in epilepsy. Expert Opin Investig Drugs. 2012; 21(9):1371-89. DOI: 10.1517/13543784.2012.705277. View

13.

Jansen M, Dannhardt G . Antagonists and agonists at the glycine site of the NMDA receptor for therapeutic interventions. Eur J Med Chem. 2003; 38(7-8):661-70. DOI: 10.1016/s0223-5234(03)00113-2. View

14.

Kawasaki-Yatsugi S, Okada M, Sakamoto S, Yatsugi S, Togami J, Hatanaka K . YM90K: pharmacological characterization as a selective and potent alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate/kainate receptor antagonist. J Pharmacol Exp Ther. 1996; 276(1):84-92. View

15.

Citraro R, Russo E, Gratteri S, Di Paola E, Ferreri Ibbadu G, Curinga C . Effects of non-competitive AMPA receptor antagonists injected into some brain areas of WAG/Rij rats, an animal model of generalized absence epilepsy. Neuropharmacology. 2006; 51(6):1058-67. DOI: 10.1016/j.neuropharm.2006.06.014. View

16.

Rodriguez-Moreno A, Sihra T . Metabotropic actions of kainate receptors in the CNS. J Neurochem. 2007; 103(6):2121-35. DOI: 10.1111/j.1471-4159.2007.04924.x. View

17.

Kohl B, Dannhardt G . The NMDA receptor complex: a promising target for novel antiepileptic strategies. Curr Med Chem. 2001; 8(11):1275-89. DOI: 10.2174/0929867013372328. View

18.

Reiner A, Levitz J . Glutamatergic Signaling in the Central Nervous System: Ionotropic and Metabotropic Receptors in Concert. Neuron. 2018; 98(6):1080-1098. PMC: 6484838. DOI: 10.1016/j.neuron.2018.05.018. View

19.

Hwa G, Avoli M, Oliver A, Villemure J . Bicuculline-induced epileptogenesis in the human neocortex maintained in vitro. Exp Brain Res. 1991; 83(2):329-39. DOI: 10.1007/BF00231156. View

20.

Lipton S, Rosenberg P . Excitatory amino acids as a final common pathway for neurologic disorders. N Engl J Med. 1994; 330(9):613-22. DOI: 10.1056/NEJM199403033300907. View